ReviewGenes & diseases2023

PCK1 dysregulation in cancer: Metabolic reprogramming, oncogenic activation, and therapeutic opportunities.

Jin Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.